Metro Morning

A not-so-new drug could lower HIV rates in Canada, doctor says

An HIV treatment drug that's already on the market in Canada may end up decreasing infection rates thanks to its recent approval by Health Canada.

Toronto General's infectious disease physician applauds approval of Truvada

Truvada, which has been recently approved by Health Canada as a drug to prevent HIV infection, costs about $900 a month without insurance. (CBC)

A drug that's already on the market in this country to treat patients who have HIV might end up decreasing infection rates, now that Health Canada has approved it as a medication to prevent the virus.

Dr. Isaac Bogoch, an infectious disease specialist at Toronto General Hospital, has been prescribing Truvada as a preventative drug for years. He said the idea that other doctors will be using Truvada the same way he does is welcome news.

Truvada is a brand name for a pill that combines two medications — emtricitabine and tenofovir disoproxil fumarate. Those, in general terms, work to stop HIV from multiplying in humans. The doctor estimates it is 85 to 99 per cent effective. And if people use it with condoms, effectiveness increases.

Dr. Isaac Bogoch spoke with Matt Galloway about Truvada, an HIV treatment that Health Canada recently approved for preventative use. Dr. Bogoch is an infectious disease specialist at Toronto General Hospital. 5:54

Bogoch has been administering it "off-label" — for different uses than its original intent — for years. But that meant it was not covered by most insurance plans.

Because of this approval, insurance companies and provinces could cover costs, which can range from $12,000 to $15,000 per year.

Based on his clinic, Bogoch said the groups who will be most likely to benefit from the drug are intravenous drug users, those who engage in unprotected sex and sex workers.

It all began in 2011, when studies showed the drug was effective as prevention as well as treatment. In 2012, the U.S. approved it for its preventative qualities. Canada's approval came on Friday.

HIV rates in Canada have levelled out, said the doctor. But steady is not as good as declining, so there's work to be done.

"This drug could get us there," he said.


To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Become a CBC Member

Join the conversation  Create account

Already have an account?